Posiflex Announces Android 10 Google Mobile Services Certification for Kiosk Platforms
23.2.2021 06:00:00 EET | Business Wire | Press release
Posiflex Technology, Inc., a world leader in the design and manufacture of retail POS, kiosk, computing, and self-service transaction peripherals, is proud to announce a new Android 10 GMS certification, applicable to the kiosk portfolio of both Posiflex and KIOSK Information Systems (KIOSK).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210222005417/en/
Powered by POSIFLEX, Certified with GMS (Graphic: Business Wire)
Posiflex CEO Owen Chen notes, “This new Android 10 GMS certification milestone is quite significant. By offering GMS Certified kiosks, it allows Google Play and other GMS applications to be installed on our Android platforms. It streamlines onboarding onto Google’s proven and secure network, while unlocking kiosk access to the full suite of applications in the Google Play Store.”
Further, as mobile devices become increasingly pervasive in delivering retail and hospitality services, corporate Mobile Device Management (MDM) platforms rely on Android or iOS compatibility to optimize efficiencies within an edge device management ecosystem. Not a problem when considering mobile devices and tablets, but robust kiosk solutions require greater durability and significantly more ability to house transaction peripherals than are provided on commercial Android tablet devices. The Android 10 GMS certified kiosk platforms are equipped with ample computing and enough USB ports to power a kiosk platform with multiple integrated transaction peripherals.
KIOSK President Kim Kenney adds, “We have seen an increased demand among major retailers and hospitality clients for Android GMS capability to access Google Play Services to register and manage their kiosk fleet within their existing infrastructure. Through the certification efforts of the Posiflex R&D Team, both KIOSK and Posiflex can now provide best-in-class self-service features that can be consistently managed through existing Android OS networks. Without question, this provides niche competitive advantage and enables us to uniquely meet important new market requirements.”
About Posiflex Group, Inc.
Posiflex has designed and manufactured world-class POS solutions for more than 30 years. Since 2016, the company has acquired KIOSK and Portwell, further expanding into self-service and embedded PC offerings. The global Posiflex Group is in place to provide world-class B2B Serviced IoT solutions. For more information: www.posiflex.com
About KIOSK Information Systems
KIOSK provides self-service automation solutions to increase operational and cost efficiencies, while enhancing the customer experience. With over 27 years of experience and >250,000+ kiosks deployed, the company is a trusted digital transformation partner for Top 100 Retailers and Fortune 500 clients. KIOSK delivers proven expertise in design engineering and manufacturing, application development, integration, and comprehensive support services. An innovative portfolio of self-service solutions paired with managed services and IoT capabilities ensure a seamless user experience. Learn more at kiosk.com, 800.509.5471.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005417/en/
Contact information
Posiflex Group Press Contact (Taiwan): Brad Chou, marketing@posiflex.com.tw
KIOSK Press Contact (US): Cheryl Madeson, VP Marketing and Communications, cmadeson@kiosk.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom